Biofrontera, Inc. Hits New 52-Week High of $1.52, Surges 57.45%

Biofrontera, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 1.52 on August 21, 2026. This achievement marks a notable increase from its 52-week low of USD 0.55, reflecting a robust performance over the past year with a gain of 57.45%. In comparison, the S&P 500 has shown a performance of 20.47% during the same period. Despite being a loss-making entity, Biofrontera's market capitalization stands at USD 10 million, indicating its position within the microcap category. The company currently has a price-to-book ratio of 0.91, suggesting that its stock is trading below its book value. Additionally, the debt-to-equity ratio is reported at -0.14, indicating a unique financial structure. However, the return on equity remains significantly negative at -109.12%, highlighting ongoing challenges in generating profits. As Biofrontera continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry, this recent price movement underscores its current market dynamics.